Orforglipron Shows Promise in Maintaining Weight Loss in Phase 3b Trial
The ATTAIN-MAINTAIN trial has demonstrated the efficacy of orforglipron, an oral GLP-1 receptor agonist, in maintaining weight loss among participants who previously underwent treatment with tirzepatide or semaglutide. Conducted across 29 sites in the U.S., the study involved 376 participants divided into two cohorts. Results showed that orforglipron helped maintain significant weight loss compared to placebo, with participants retaining up to 79.3% of their weight reduction. The trial also highlighted the safety profile of orforglipron, with gastrointestinal issues being the most common side effects. This study marks a significant step in transitioning from injectable to oral weight management therapies. 
